« Previous
Next »
Titles
- Antiandrogen therapies for nonmetastatic castration-resistant prostate cancer: effectiveness and value : final evidence report1
- Are you ready to respond?: reports of high harm complications after surgery and invasive procedures1
- Biologic therapies for treatment of asthma associated with type 2 inflammation: effectiveness, value, and value-based price benchmarks : final evidence report1
- Calcitonin gene-related peptide (CGRP) inhibitors as preventive treatments for patients with episodic or chronic migraine: effectiveness and value : final evidence report1
- Chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value : final evidence report1
- Elagolix for treating endometriosis: final evidence report1
- Emicizumab for hemophilia A with inhibitors: effectiveness and value : final evidence report1
- Extended-release opioid agonists and antagonist medications for addiction treatment (MAT) in patients with opioid use disorder: effectiveness and value : final evidence report1
- Inotersen and patisiran for hereditary transthyretin amyloidosis: effectiveness and value : final evidence report1
- Modulator treatments for cystic fibrosis: effectiveness and value : final evidence report and meeting summary1
- Prophylaxis for hereditary angioedema with lanadelumab and C1 Inhibitors: effectiveness and value : final evidence report1
- Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value : condition update : final evidence report1
- Voretigene neparvovec for biallelic RPE65-mediated retinal disease: effectiveness and value : final evidence report1